Cybin Inc.
Marking a world first, researchers at Imperial’s Centre for Psychedelic Research will investigate psilocybin as a treatment for gambling addiction with the support of funding from...
The final cohort of patients has been dosed in Cybin’s Dosing Phase 2 Trial investigating CYB003 – an investigational deuterated analogue of psilocybin – as a...
A low-cost version of ketamine has shown promising results in its treatment of resistant depression in a double-blind trial.
Until now, it has been commonly thought that selective serotonin reuptake inhibitors (SSRIs) could interfere with the therapeutic potential of psilocybin treatment.
The UK’s Medicines and Healthcare Products Regulatory Authority (MHRA) has approved a trial investigating psilocin for major depressive disorder (MDD) that will be carried out in...
A study has been launched that is investigating COMP360 psilocybin therapy – an investigational new therapy – for treatment-resistant depression (TRD).
New data released by Sunstone Therapies shows positive long-term follow-up results from psilocybin therapy in cancer patients with major depressive disorder (MDD).
Subanaesthetic intravenous ketamine has been shown to be as effective and not inferior to electroconvulsive therapy (ECT) for the treatment of non-psychotic, treatment-resistant depression.
Two new drug candidates have been developed for the treatment of addiction and depression that have been modelled on the pharmacology of a traditional African psychoactive...
